Rezolute (RZLT) Stock Price, News & Analysis

Company Overview

Rezolute, Inc. (NASDAQ: RZLT) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for endocrine and metabolic disorders with significant unmet medical needs. The company’s lead candidate, RZ358, is an investigational monoclonal antibody designed to modulate insulin receptor activity and normalize aberrant insulin signaling in conditions such as congenital hyperinsulinism. Rezolute’s pipeline also includes RZ402, a novel long-acting basal insulin analog engineered to provide stable glycemic control while minimizing the risk of hypoglycemia in patients with type 1 and type 2 diabetes.

Founded in 2015 and headquartered in San Diego, California, Rezolute has built a proprietary research platform that integrates advanced antibody engineering, peptide formulation, and translational pharmacology. This platform underpins early-stage programs targeting hormonal pathways implicated in rare endocrine diseases and inflammatory metabolic conditions. By leveraging precise molecular design and biomarker-driven strategies, the company aims to accelerate the development of first-in-class and best-in-class therapeutics.

Rezolute collaborates with leading academic institutions and contract research organizations across North America and Europe to support its preclinical and clinical activities. Its clinical trials are structured to yield robust mechanistic insights and facilitate regulatory engagement, reflecting a commitment to evidence-based, patient-centric development. The company’s global strategy includes expanding trial sites and forging partnerships to ensure broad access to its investigational therapies.

Under the leadership of a seasoned management team with deep expertise in biotechnology, endocrinology, and pharmaceutical development, Rezolute maintains a lean operational model focused on scientific rigor and innovation. The company’s multidisciplinary staff spans drug discovery, clinical pharmacology, and regulatory affairs, positioning Rezolute to address complex hormonal disorders and advance therapeutic options for patients worldwide.

Key Stats

• Today's Range: $5.34 to $5.60
• 50-Day Range: $3.49 to $5.54
• 52-Week Range: $2.22 to $6.19
• Volume: 250,531 shs
• Average Volume: 670,045 shs
• Market Capitalization: $472.85 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.83
• Consensus Rating: Buy

Rezolute Stock Analysis - MarketRank™

Rezolute scored higher than 49% of companies evaluated by MarketBeat, and ranked 538th out of 918 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Rezolute has received a consensus rating of Buy. The company's average rating score is 3.14, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Rezolute has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Rezolute are expected to decrease in the coming year, from ($0.93) to ($1.15) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Rezolute is -4.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Rezolute is -4.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Rezolute has a P/B Ratio of 2.48. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.84% of the float of Rezolute has been sold short.

Short Interest Ratio / Days to Cover

Rezolute has a short interest ratio ("days to cover") of 6.3.

Change versus previous month

Short interest in Rezolute has recently increased by 60.70%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Rezolute does not currently pay a dividend.

Dividend Growth

Rezolute does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

11.84% of the float of Rezolute has been sold short.

Short Interest Ratio / Days to Cover

Rezolute has a short interest ratio ("days to cover") of 6.3.

Change versus previous month

Short interest in Rezolute has recently increased by 60.70%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.8 / 5
• News Sentiment: 0.30

News Sentiment

Rezolute has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Rezolute this week, compared to 3 articles on an average week.

Search Interest

Only 3 people have searched for RZLT on MarketBeat in the last 30 days. This is a decrease of -70% compared to the previous 30 days.

MarketBeat Follows

3 people have added Rezolute to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Rezolute insiders have bought more of their company's stock than they have sold. Specifically, they have bought $4,041,196.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

18.39% of the stock of Rezolute is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

82.97% of the stock of Rezolute is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

RZLT Stock Analysis - Frequently Asked Questions

How have RZLT shares performed this year?

Rezolute's stock was trading at $4.90 at the beginning of the year. Since then, RZLT stock has increased by 10.9% and is now trading at $5.4350.

How were Rezolute's earnings last quarter?

Rezolute, Inc. (NASDAQ:RZLT) issued its earnings results on Tuesday, May, 13th. The company reported ($0.27) EPS for the quarter, missing analysts' consensus estimates of ($0.22) by $0.05.

Who are Rezolute's major shareholders?

Top institutional shareholders of Rezolute include Retireful LLC (0.02%). Insiders that own company stock include Young-Jin Kim, Daron Evans, Nevan C Elam, Nevan C Elam, Wladimir Hogenhuis, Wladimir Hogenhuis, Nerissa Kreher and Brian Kenneth Roberts.
View institutional ownership trends.

How do I buy shares of Rezolute?

Shares of RZLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Rezolute own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Rezolute investors own include Meta Platforms (META), NVIDIA (NVDA), PayPal (PYPL), Advanced Micro Devices (AMD), Taiwan Semiconductor Manufacturing (TSM), CrowdStrike (CRWD) and Vanguard S&P 500 ETF (VOO).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 7/21/2025
• Next Earnings (Estimated): 9/18/2025
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:RZLT
• CIK: 1509261
• Web: www.rezolutebio.com
• Phone: (650) 206-4507
• Fax: N/A
• Employees: 40
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Rezolute: $11.83
• High Price Target: $15.00
• Low Price Target: $9.00
• Potential Upside/Downside: +119.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.14
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.15)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$68.46 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -70.09%
• Return on Assets: -63.08%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.43
• Quick Ratio: 8.43

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.19 per share
• Price / Book: 2.46

Miscellaneous

• Outstanding Shares: 87,000,000
• Free Float: 70,997,000
• Market Cap: $468.93 million
• Optionable: Optionable
• Beta: 1.03